Exhaled phospholipid transfer protein and hepatocyte growth factor receptor in lung adenocarcinoma
(2022) In Respiratory Research 23(1). p.1-10- Abstract
BACKGROUND: Screening decreases mortality among lung cancer patients but is not widely implemented, thus there is an unmet need for an easily accessible non-invasive method to enable early diagnosis. Particles in exhaled air offer a promising such diagnostic tool. We investigated the validity of a particles in exhaled air device (PExA) to measure the particle flow rate (PFR) and collect exhaled breath particles (EBP) to diagnose primary lung adenocarcinoma (LUAD).
METHODS: Seventeen patients listed for resection of LUAD stages IA-IIIA and 18 non-cancer surgical control patients were enrolled. EBP were collected before and after surgery for LUAD, and once for controls. Proteomic analysis was carried out using a proximity extension... (More)
BACKGROUND: Screening decreases mortality among lung cancer patients but is not widely implemented, thus there is an unmet need for an easily accessible non-invasive method to enable early diagnosis. Particles in exhaled air offer a promising such diagnostic tool. We investigated the validity of a particles in exhaled air device (PExA) to measure the particle flow rate (PFR) and collect exhaled breath particles (EBP) to diagnose primary lung adenocarcinoma (LUAD).
METHODS: Seventeen patients listed for resection of LUAD stages IA-IIIA and 18 non-cancer surgical control patients were enrolled. EBP were collected before and after surgery for LUAD, and once for controls. Proteomic analysis was carried out using a proximity extension assay technology. Results were validated in both plasma from the same cohort and with microarray data from healthy lung tissue and LUAD tissue in the GSE10072 dataset.
RESULTS: Of the 92 proteins analyzed, levels of five proteins in EBP were significantly higher in the LUAD patients compared to controls. Levels of phospholipid transfer protein (PLTP) and hepatocyte growth factor receptor (MET) decreased in LUAD patients after surgery compared to control patients. PFR was significantly higher in the LUAD cohort at all timepoints compared to the control group. MET in plasma correlated significantly with MET in EBP.
CONCLUSION: Collection of EBP and measuring of PFR has never been performed in patients with LUAD. In the present study PFR alone could distinguish between LUAD and patients without LUAD. PLTP and MET were identified as potential biomarkers to evaluate successful tumor excision.
(Less)
- author
- Andreasson, Jesper LU ; Bodén, Embla LU ; Fakhro, Mohammed LU ; von Wachter, Camilla ; Olm, Franziska LU ; Malmsjö, Malin LU ; Hallgren, Oskar LU and Lindstedt, Sandra LU
- organization
-
- StemTherapy: National Initiative on Stem Cells for Regenerative Therapy
- DCD transplantation of lungs (research group)
- Department of Clinical Sciences, Lund
- Ophthalmology Imaging Research Group (research group)
- Clinical and experimental lung transplantation (research group)
- NPWT technology (research group)
- Thoracic Surgery
- LUCC: Lund University Cancer Centre
- WCMM-Wallenberg Centre for Molecular Medicine
- publishing date
- 2022-12-21
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Humans, Phospholipid Transfer Proteins, Proto-Oncogene Proteins c-met, Proteomics, Adenocarcinoma of Lung/diagnosis, Lung Neoplasms/diagnosis, Biomarkers, Tumor/genetics
- in
- Respiratory Research
- volume
- 23
- issue
- 1
- article number
- 369
- pages
- 1 - 10
- publisher
- BioMed Central (BMC)
- external identifiers
-
- scopus:85144557870
- pmid:36544145
- ISSN
- 1465-9921
- DOI
- 10.1186/s12931-022-02302-4
- language
- English
- LU publication?
- yes
- additional info
- © 2022. The Author(s).
- id
- f0caef7e-1196-4ea1-9723-76c08645f9c5
- date added to LUP
- 2022-12-26 18:11:54
- date last changed
- 2024-04-18 07:39:42
@article{f0caef7e-1196-4ea1-9723-76c08645f9c5, abstract = {{<p>BACKGROUND: Screening decreases mortality among lung cancer patients but is not widely implemented, thus there is an unmet need for an easily accessible non-invasive method to enable early diagnosis. Particles in exhaled air offer a promising such diagnostic tool. We investigated the validity of a particles in exhaled air device (PExA) to measure the particle flow rate (PFR) and collect exhaled breath particles (EBP) to diagnose primary lung adenocarcinoma (LUAD).</p><p>METHODS: Seventeen patients listed for resection of LUAD stages IA-IIIA and 18 non-cancer surgical control patients were enrolled. EBP were collected before and after surgery for LUAD, and once for controls. Proteomic analysis was carried out using a proximity extension assay technology. Results were validated in both plasma from the same cohort and with microarray data from healthy lung tissue and LUAD tissue in the GSE10072 dataset.</p><p>RESULTS: Of the 92 proteins analyzed, levels of five proteins in EBP were significantly higher in the LUAD patients compared to controls. Levels of phospholipid transfer protein (PLTP) and hepatocyte growth factor receptor (MET) decreased in LUAD patients after surgery compared to control patients. PFR was significantly higher in the LUAD cohort at all timepoints compared to the control group. MET in plasma correlated significantly with MET in EBP.</p><p>CONCLUSION: Collection of EBP and measuring of PFR has never been performed in patients with LUAD. In the present study PFR alone could distinguish between LUAD and patients without LUAD. PLTP and MET were identified as potential biomarkers to evaluate successful tumor excision.</p>}}, author = {{Andreasson, Jesper and Bodén, Embla and Fakhro, Mohammed and von Wachter, Camilla and Olm, Franziska and Malmsjö, Malin and Hallgren, Oskar and Lindstedt, Sandra}}, issn = {{1465-9921}}, keywords = {{Humans; Phospholipid Transfer Proteins; Proto-Oncogene Proteins c-met; Proteomics; Adenocarcinoma of Lung/diagnosis; Lung Neoplasms/diagnosis; Biomarkers, Tumor/genetics}}, language = {{eng}}, month = {{12}}, number = {{1}}, pages = {{1--10}}, publisher = {{BioMed Central (BMC)}}, series = {{Respiratory Research}}, title = {{Exhaled phospholipid transfer protein and hepatocyte growth factor receptor in lung adenocarcinoma}}, url = {{http://dx.doi.org/10.1186/s12931-022-02302-4}}, doi = {{10.1186/s12931-022-02302-4}}, volume = {{23}}, year = {{2022}}, }